|
|
Download the plasmid map
Use BVTech Plasmid to view and edit this plasmid map.
Dowload BVTech Plasmid
If you do not have BVTech Plasmid, download the latest version of BVTech Plasmid here.
BVTech Plasmid is DNA sequence analysis and plasmid drawing software for Windows PCs.
You can use it to plan your DNA cloning, draw high quality plasmid maps, analyse your
DNA sequencing data, align sequences, and much more.
Free to try, $39.98 to buy
Payments will be processed by PayPal. PayPal is the safer, easier way to pay.
|
View the sequence with features on line pRL-TK CXCR4 2x Gene/insert name: 2 bulged bind sites for CXCR4 siRNA antisense Insert size (bp): 69 Fusion proteins or tags: Rr-luc Terminal: N terminal on backbone Vector backbone: pRL-TK (Search Vector Database) Backbone manufacturer: Promega Type of vector: Luciferase Backbone size (bp): 4118 Cloning site 5': XbaI Site destroyed during cloning: No Cloning site 3': ApaI Site destroyed during cloning: No 5' Sequencing primer: See map (List of Sequencing Primers) 3' Sequencing primer: EBV-rev Bacteria resistance: Ampicillin High or low copy: High Copy Grow in standard E. coli @ 37C: Yes Principal Investigator: Phil Sharp Comments: The end of the ORF and the beginning of the 3' UTR is (with the TAA stop codon, followed by T, then the XbaI site TCTAGA): AAATGAACAA TAA T TCTAGA GCGGCCGCT. We digested the plasmids with XbaI, and ligated in the following: ctaga ttccgagatatcggtaat gggcc. This produced a modified vector, still containing an XbaI site, but now also containing an ApaI site (GGGCCC), to allow for directional cloning of 3' UTR inserts. The final vector contains, starting with the stop codon TAA: TAA T Tctaga ttccgagatatcggtaat gggccC TAGA. All UTR inserts were then constructed in the following format: TCTAGA CTCGAGCCGG[binding site]ATCGC GGGCCC. A single perfect site sequence is AAGTTTTCACTCCAGCTAACACCGG. CXCR4 siRNA used is GUUUUCACUCCAGCUAACACATTCAAAAGUGAGGUCGAUUGU. Article: siRNAs can function as miRNAs. Doench JG et al. (Genes Dev. 2003 Feb 15. 17(4):438-42. Pubmed)
|